Literature DB >> 12145486

The DSM series and experience with DSM-IV.

Michael B First1.   

Abstract

DSM-IV is the standard language for psychiatric diagnosis in the United States. An unanticipated consequence of DSM-III is international interest in this American document; for example, DSM-III was translated into 13 languages. This was due to its adopting a descriptive classification that eschewed etiologic theory and contained operational definitions, following Stengel's recommendations in his WHO report in 1959. These principles were eventually implemented in ICD-10, with the result of being two somewhat different classification systems. Although WHO-APA collaborations have minimized differences, a significant number remains, with only a few reflecting true ideological differences. The challenge for the future will be to integrate the two systems to produce, as much as possible, a unified system for international diagnostic communication. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12145486     DOI: 10.1159/000065121

Source DB:  PubMed          Journal:  Psychopathology        ISSN: 0254-4962            Impact factor:   1.944


  33 in total

1.  Prefrontal cortical response to emotional faces in individuals with major depressive disorder in remission.

Authors:  Rebecca Kerestes; Zubin Bhagwagar; Pradeep J Nathan; Shashwath A Meda; Cecile D Ladouceur; Kathleen Maloney; David Matuskey; Barbara Ruf; Aybala Saricicek; Fei Wang; Godfrey D Pearlson; Mary L Phillips; Hilary P Blumberg
Journal:  Psychiatry Res       Date:  2012-05-16       Impact factor: 3.222

2.  Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism.

Authors:  S Jamadar; E E DeVito; R E Jiantonio; S A Meda; M C Stevens; M N Potenza; J H Krystal; G D Pearlson
Journal:  Psychopharmacology (Berl)       Date:  2012-02-04       Impact factor: 4.530

3.  The effects of methylphenidate and propranolol on the interplay between induced-anxiety and working memory.

Authors:  Monique Ernst; Tiffany Lago; Andrew Davis; Christian Grillon
Journal:  Psychopharmacology (Berl)       Date:  2016-08-05       Impact factor: 4.530

4.  Affective Correlates of Psychosis in Parkinson's Disease.

Authors:  Stewart A Factor; Michael K Scullin; Alan Freeman; Donald L Bliwise; William M McDonald; Felicia C Goldstein
Journal:  Mov Disord Clin Pract       Date:  2016-06-16

5.  Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.

Authors:  Jie Zhang; Chadi G Abdallah; Junqing Wang; Xiaona Wan; Chunlian Liang; Liyun Jiang; Yuzhen Liu; Haixing Huang; Xiaohong Hong; Qingjun Huang; Renhua Wu; Chongtao Xu
Journal:  Psychiatry Res       Date:  2012-06-16       Impact factor: 3.222

6.  Gender and treatment response in substance use treatment-mandated parolees.

Authors:  Jennifer E Johnson; Peter D Friedmann; Traci C Green; Magdalena Harrington; Faye S Taxman
Journal:  J Subst Abuse Treat       Date:  2011-01-26

7.  Exercise modulates the interaction between cognition and anxiety in humans.

Authors:  Tiffany R Lago; Abigail Hsiung; Brooks P Leitner; Courtney J Duckworth; Nicholas L Balderston; Kong Y Chen; Christian Grillon; Monique Ernst
Journal:  Cogn Emot       Date:  2018-07-23

8.  Collaborative behavioral management: integration and intensification of parole and outpatient addiction treatment services in the Step'n Out study.

Authors:  Peter D Friedmann; Anne G Rhodes; Faye S Taxman
Journal:  J Exp Criminol       Date:  2009-09-01

9.  Evidence for anomalous network connectivity during working memory encoding in schizophrenia: an ICA based analysis.

Authors:  Shashwath A Meda; Michael C Stevens; Bradley S Folley; Vince D Calhoun; Godfrey D Pearlson
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

10.  Critical evaluation of current diagnostic systems.

Authors:  Claudio E M Banzato
Journal:  Indian J Psychiatry       Date:  2008-07       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.